BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30047605)

  • 1. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.
    Zhang M; Wang S; Wilffert B; Tong R; van Soolingen D; van den Hof S; Alffenaar JW
    Br J Clin Pharmacol; 2018 Dec; 84(12):2747-2760. PubMed ID: 30047605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
    Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.
    Yuliwulandari R; Prayuni K; Susilowati RW; M Sofro AS; Tokunaga K; Shin JG
    Pharmacogenomics; 2019 Dec; 20(18):1303-1311. PubMed ID: 31699005
    [No Abstract]   [Full Text] [Related]  

  • 4. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.
    Yuliwulandari R; Susilowati RW; Wicaksono BD; Viyati K; Prayuni K; Razari I; Kristin E; Syafrizal ; Subagyo ; Sri Diana E; Setiawati S; Ariyani A; Mahasirimongkol S; Yanai H; Mushiroda T; Tokunaga K
    J Hum Genet; 2016 Jun; 61(6):533-7. PubMed ID: 26911349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.
    Suvichapanich S; Fukunaga K; Zahroh H; Mushiroda T; Mahasirimongkol S; Toyo-Oka L; Chaikledkaew U; Jittikoon J; Yuliwulandari R; Yanai H; Wattanapokayakit S; Tokunaga K
    Pharmacogenet Genomics; 2018 Jul; 28(7):167-176. PubMed ID: 29781872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
    Wang PY; Xie SY; Hao Q; Zhang C; Jiang BF
    Int J Tuberc Lung Dis; 2012 May; 16(5):589-95. PubMed ID: 22409928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.
    Perwitasari DA; Darmawan E; Mulyani UA; Vlies PV; Alffenaar JC; Atthobar J; Wilffert B
    Int J Mycobacteriol; 2018; 7(4):380-386. PubMed ID: 30531039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of genetic polymorphisms of
    Yang S; Hwang SJ; Park JY; Chung EK; Lee JI
    BMJ Open; 2019 Aug; 9(8):e027940. PubMed ID: 31375612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.
    Chan SL; Chua APG; Aminkeng F; Chee CBE; Jin S; Loh M; Gan SH; Wang YT; Brunham LR
    PLoS One; 2017; 12(10):e0186200. PubMed ID: 29036176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
    Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
    Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
    Gupta VH; Amarapurkar DN; Singh M; Sasi P; Joshi JM; Baijal R; Ramegowda PH; Amarapurkar AD; Joshi K; Wangikar PP
    J Gastroenterol Hepatol; 2013 Aug; 28(8):1368-74. PubMed ID: 23875638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.
    Ng CS; Hasnat A; Al Maruf A; Ahmed MU; Pirmohamed M; Day CP; Aithal GP; Daly AK
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1079-86. PubMed ID: 24888881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.
    Shi J; Xie M; Wang J; Xu Y; Liu X
    Pharmacogenomics; 2015 Dec; 16(18):2083-97. PubMed ID: 26616266
    [TBL] [Abstract][Full Text] [Related]  

  • 14.  NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population.
    Lv X; Tang S; Xia Y; Zhang Y; Wu S; Yang Z; Li X; Tu D; Chen Y; Deng P; Ma Y; Chen D; Chen R; Zhan S
    Ann Hepatol; 2012; 11(5):700-7. PubMed ID: 22947533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis.
    Du H; Chen X; Fang Y; Yan O; Xu H; Li L; Li W; Huang W
    Mol Biol Rep; 2013 May; 40(5):3591-6. PubMed ID: 23277397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
    Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD
    Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients.
    An HR; Wu XQ; Wang ZY; Zhang JX; Liang Y
    Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):535-43. PubMed ID: 22506592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients.
    Jaramillo-Valverde L; Levano KS; Tarazona DD; Capristano S; Zegarra-Chapoñan R; Sanchez C; Yufra-Picardo VM; Tarazona-Santos E; Ugarte-Gil C; Guio H
    Mol Genet Genomic Med; 2022 Aug; 10(8):e1987. PubMed ID: 35751408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
    Azuma J; Ohno M; Kubota R; Yokota S; Nagai T; Tsuyuguchi K; Okuda Y; Takashima T; Kamimura S; Fujio Y; Kawase I;
    Eur J Clin Pharmacol; 2013 May; 69(5):1091-101. PubMed ID: 23150149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The associations of polymorphism of N-acetyltransferase 2 gene is associated with antituberculosis drug-induced hepatotoxicity in tuberculosis patients].
    An HR; Wu XQ; Wang ZY; Liang Y; Zhang JX
    Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Jan; 45(1):36-40. PubMed ID: 21418817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.